Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Linda Stein Gold, MD

Emerging Psoriasis, PsA Drugs and Future Developments in Dermatology, With Linda Stein Gold, MD

 titled ‘Best of the Best at Maui Derm,’ during which its 2 presenters highlighted recent data in the psoriasis treatment space on emerging therapeutic agents.

Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, presented this talk. Stein Gold, who previously touched on these findings in an 

 interview, was asked in this video about what stood out in the panel discussion about improving early recognition of psoriatic arthritis (PsA).

“When we think about our psoriasis patients, we have to remember that this is a systemic disease, and psoriatic arthritis is one of those manifestations that occurs quite commonly in our psoriasis patients,” Stein Gold explained.

Stein Gold noted during certain times, clinicians should have the potential for PsA development at front of mind. Such patients will specifically have scalp involvement or nail involvement. These patients may require substantial attention in terms of early PsA detection.

Later, Stein Gold was asked about practicing clinicians trying to navigate an increasingly complex therapeutic landscape. Specifically, she was asked which guiding principles she would emphasize when choosing among new and established psoriasis treatments.

“It can be very confusing when we look at our current options and our new options for psoriasis patients, but I think we really owe it to ourselves and to our patients to understand what's going on with each new drug,” Stein Gold explained. “We don't have to know every single drug, but we should get to know drugs in particular categories. Get to know a really good IL-23 drug and IL-17 drug, maybe a TNF-inhibitor, that you're comfortable with. Then let's look at the newer oral agents. Let's look at the TYK2 inhibitors.”

To find out more on the topics covered here, view Stein Gold’s full video above. For more from Maui Derm, view the 

The quotes used in this interview summary were edited for clarity.

Disclosures: Stein Gold has reported serving as an investigator, advisor, or speaker for AbbVie, Amgen, Arctis, Bristol Myers Squibb, Dermavant, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. AWA has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Arcutis, BMS, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Galderma, Incyte, Johnson & Johnson, Leo Pharma, Novartis, Parexel, Pfizer, Regeneron, Sanofi, Takeda, and UCB. RB is an advisory board member, consultant, speaker, investigator for, or received honoraria or grants from AbbVie, Alumis, Amgen, AnaptysBio, Arcutis, BMS/Celgene, Eli Lilly, Johnson & Johnson, LEO Pharma, Organon, Nimbus, Takeda, UCB, VentyxBio, Vyne, Xencor, and Zurabio, and is also an employee and shareholder of Innovaderm Research.

Stein Gold L, Hawkes J. Best of the Best at Maui Derm. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29.

Armstrong AW, Gooderham M, Papp K, et al. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial. JAMA Dermatol. 2024 Oct 1;160(10):1066-1074. doi: 10.1001/jamadermatol.2024.2701. PMID: 39167366; PMCID: PMC11339701.

Videos

This interview with Stein Gold continues her discussion of new and emerging psoriasis therapies in 2026.

Discussing Icotrokinra for Adolescents, Other Emerging Psoriasis Drugs, With Linda Stein Gold, MD

, held at the Grand Wailea hotel, featured a presentation titled ‘Best of the Best at Maui Derm’ highlighting some of the key recent data on emerging therapeutic agents.

This session was presented by Linda Stein Gold, MD, director of Dermatology Clinical Research for the Henry Ford Health System, and Jason Hawkes, MD, associate professor of dermatology at the University of California, Davis, in Sacramento. Stein Gold sat down with 

 to discuss some of the most notable information highlighted in this talk.

“I think that in 2026, we understand that we have options available for our psoriasis patients to get them under control better than we have in the past, and we have wonderful options in the topical arena. We have these new nonsteroidal options that actually allow us to get patients under control and keep them under control.”

Additionally, Stein Gold highlighted efficacy rates of some of the new non-steroidals as higher than more traditional non-steroidal options in the past. Such options may help to simplify the treatment regimens among patients with psoriasis. Stein Gold also highlighted biologic agents getting patients to clear or almost clear and working well for psoriatic arthritis (PsA). Stein Gold was later asked about any specific drugs on the horizon with a significant amount of data behind them.

“We have one oral agent, icotrokinra…and this is a drug that's actually an oral peptide,” Stein Gold said. “It's different from the small molecules in the biologic [realm], and it's been formulated to be better absorbed. This drug actually targets the IL-23 receptor.”

Stein Gold noted icotrokinra was developed to selectively bind the interleukin (IL)-23 receptor and inhibit IL-23–mediated signaling. The medication’s use in patients with moderate-to-severe plaque psoriasis was explored in a variety of phase 3 clinical trials, including LEAD, ADVANCE 1, and ADVANCE 2.2 Stein Gold’s talk at Maui Derm included a discussion of data in adolescent patients specifically.

“We had a recent readout there where the efficacy data is really quite good, long term data does not show any safety signals that we seem to be concerned about,” Stein Gold explained. “We know that when we stop treatment with this drug, we see that we have about 8 - 12 weeks before we lose a PASI 90 or a PASI 75 response.”

For any additional information on these topics, view Stein Gold’s full interview posted above. To find out more from Maui Derm, view the 

The quotes contained in this interview were edited for clarity.

Armstrong A, et al. Comparative analysis of icotrokinra and approved advanced treatments for achievement of completely clear skin in patients with moderate-to-severe psoriasis: A systematic literature review and network meta-analysis. Presented at the 2026 Maui Derm Hawaii Conference, January 25-29. Accessed January 28, 2026.

This interview at the 2026 Maui Derm Hawaii meeting features a discussion of new and emerging therapies in psoriasis, including icotrokinra.

Final reflections from physicians Stein Gold, Soung, and Cotter, emphasizing multidisciplinary, patient-focused advances in psoriasis and PsA care.

Closing Thoughts on the Impact of IL-23s in Psoriasis and Psoriatic Arthritis

, despite the expanding therapeutic landscape. Linda Stein Gold, MD, and her colleagues analyze patient- and provider-reported data from the 

 surveys, revealing that many patients remain dissatisfied with current therapies and that oral agents are overwhelmingly preferred over injectables. The experts discuss how patient lifestyle, comorbidities, and psychosocial burden influence shared decision-making and treatment adherence. They also interpret the 

International Psoriasis Council’s (IPC)

 and explore its implications for reducing “topical churn” and advancing systemic therapy earlier in the disease course.

 and its potential to close current gaps in care. The panel provides an in-depth review of the 

 clinical development program, summarizing the 

 trials, which demonstrated superior efficacy versus deucravacitinib at both 16 and 24 weeks, with favorable safety and tolerability. They also discuss new 

 showing sustained clearance and no new safety signals in adults and adolescents. The faculty reflect on ICO’s implications for adolescent psoriasis and how early, aggressive oral intervention may help prevent progression to psoriatic arthritis, marking a significant milestone in the evolution of oral IL-23–targeted therapy.

The final portion of the series shifts focus to 

managing active psoriatic arthritis (PsA)

. The experts discuss new findings from the 

 demonstrated the first clear evidence of IL-23–mediated inhibition of structural joint damage, reinforcing the rationale for early biologic use in high-risk patients. They compare APEX to prior IL-23 studies, discuss implications for therapy sequencing, and highlight other emerging data from 

 studies. In closing, Stein Gold and colleagues emphasize a forward-looking approach that integrates personalized therapy selection, early detection of PsA, and cross-specialty collaboration to elevate standards of psoriasis care

Highlights from Fall Clinical 2025, including emerging IL-23 and real-world data shaping the next phase of psoriasis research.

Linda Stein Gold, MD

Articles